Pharsight

Samsca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501730 OTSUKA Process for preparing benzazepine compounds or salts thereof
Sep, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5258510 OTSUKA Benzoheterocyclic compounds
Nov, 2012

(11 years ago)

US5753677 OTSUKA Benzoheterocyclic compounds
May, 2015

(9 years ago)

US10905694 OTSUKA Pharmaceutical solid preparation comprising benzazepines and production method thereof
Apr, 2030

(5 years from now)

Samsca is owned by Otsuka.

Samsca contains Tolvaptan.

Samsca has a total of 4 drug patents out of which 2 drug patents have expired.

Expired drug patents of Samsca are:

  • US5258510
  • US5753677

Samsca was authorised for market use on 19 May, 2009.

Samsca is available in tablet;oral dosage forms.

Samsca can be used as method of treating hyponatremia.

Drug patent challenges can be filed against Samsca from 19 May, 2013.

The generics of Samsca are possible to be released after 07 April, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 19, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TOLVAPTAN ingredient

NCE-1 date: 19 May, 2013

Market Authorisation Date: 19 May, 2009

Treatment: Method of treating hyponatremia

Dosage: TABLET;ORAL

How can I launch a generic of SAMSCA before it's drug patent expiration?
More Information on Dosage

SAMSCA family patents

Family Patents